147 related articles for article (PubMed ID: 31346887)
1. Management of Ileal Neuroendocrine Tumors with Liver Metastases.
Fisher AT; Titan AL; Foster DS; Worth PJ; Poultsides GA; Visser BC; Dua MM; Norton JA
J Gastrointest Surg; 2020 Jul; 24(7):1530-1539. PubMed ID: 31346887
[TBL] [Abstract][Full Text] [Related]
2. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
4. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
5. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
[TBL] [Abstract][Full Text] [Related]
6. Hepatic surgery for metastases from neuroendocrine tumors.
Sarmiento JM; Que FG
Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
[TBL] [Abstract][Full Text] [Related]
9. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
10. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
11. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
[TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
[TBL] [Abstract][Full Text] [Related]
17. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
18. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution.
Dahdaleh FS; Calva-Cerqueira D; Carr JC; Liao J; Mezhir JJ; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2012 Mar; 19(3):966-72. PubMed ID: 21845496
[TBL] [Abstract][Full Text] [Related]
20. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.
Ni K; Yang JY; Baeg K; Leiter AC; Mhango G; Gallagher EJ; Wisnivesky JP; Kim MK
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1387. PubMed ID: 33835729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]